STE$267.99
$268.37
Chart
Performance
Key Stats
AI STE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySTERIS demonstrates strong fundamentals, particularly in profitability and balance sheet health, with a stable dividend. While recent performance shows a slight dip, the company's positioning in healthcare and life sciences offers defensive qualities and steady growth potential. Technicals suggest a neutral to slightly bullish short-term outlook.
Thematic
STERIS benefits from long-term growth trends in healthcare, medical technology, and infection prevention. Its diversified business model across healthcare, life sciences, and applied sterilization technologies provides resilience.
Fundamental
STERIS exhibits robust profitability, consistent revenue growth, and a strong balance sheet. The company's P/E ratio is on the higher side, but its stable earnings and dividend support its valuation.
Technical
STERIS's technical indicators are mixed. While it's trading above key long-term moving averages, shorter-term indicators suggest potential consolidation or a slight pullback. The stock is within its 52-week range.
| Factor | Score |
|---|---|
| Healthcare Spending Growth | 85 |
| Infection Prevention & Sterilization | 90 |
| Life Sciences Demand | 70 |
| Regulatory Environment (Healthcare) | 70 |
| Global Expansion | 70 |
| Factor | Score |
|---|---|
| Valuation | 55 |
| Profitability | 85 |
| Growth | 80 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Short-term Sentiment | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent EPS Beats
The company has exceeded EPS estimates for the last 8 reported quarters, with an average surprise of 5.61%, indicating reliable earnings performance.
Attractive P/E Ratio
The trailing P/E ratio of 36.89, while seemingly high, is justified by the company's strong EPS growth, as evidenced by its P/E to Growth (PEG) ratio (implied by EPS growth vs. P/E) suggesting potential undervaluation.
Bearish Points (7)
High Price-to-Sales Ratio
The TTM P/S ratio of 5.3 is higher than its 2023 ratio of 4.1, potentially indicating that the stock is becoming more expensive relative to its sales.
Mixed Quarterly Revenue Growth
While annual revenue has grown, recent quarterly revenue figures (e.g., 2025Q1 revenue of $1.48 billion) show a deceleration compared to the previous year's quarters, which warrants monitoring for future expansion.
Calendar
June 2025
10
Ex-Dividend Date
June 2025
26
Next Dividend Date
August 2025
7
Next Earnings Date
H: $2.33
A: $2.26
L: $2.18
H: 1.37B
A: 1.36B
L: 1.35B
Profile
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Seasonals
Price Target
264.43 USD
The 39 analysts offering 1 year price forecasts for STE have a max estimate of 288.00 and a min estimate of 231.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in HVAC systems and building solutions, a core segment of STE.
Weight: 97
Direct competitor in HVAC systems and services, a primary focus for STE.
Weight: 95
Major manufacturer of heating, ventilation, air conditioning, and refrigeration products; direct competitor in commercial HVAC.
Weight: 92
Major competitor in building technologies, including HVAC, fire, security, and controls, overlapping with STE's building solutions.